Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections.
- DOI
- 10.1007/s10198-025-01891-3
- Published
- 2026 Feb 7
- Container
- The European journal of health economics : HEPAC : health economics in prevention and care
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10198-025-01891-3,
title = {Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections.},
author = {Manders EA and van Der Wel V and Schlingemann R and Hollak CEM and de Visser SJ},
year = {2026},
journal = {The European journal of health economics : HEPAC : health economics in prevention and care},
doi = {10.1007/s10198-025-01891-3},
url = {https://doi.org/10.1007/s10198-025-01891-3}
}RIS
TY - JOUR TI - Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections. AU - Manders EA AU - van Der Wel V AU - Schlingemann R AU - Hollak CEM AU - de Visser SJ PY - 2026 JO - The European journal of health economics : HEPAC : health economics in prevention and care DO - 10.1007/s10198-025-01891-3 UR - https://doi.org/10.1007/s10198-025-01891-3 ER -
APA
EA, M., V, V. D. W., R, S., CEM, H., & SJ, D. V. (2026). Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections.. The European journal of health economics : HEPAC : health economics in prevention and care. https://doi.org/10.1007/s10198-025-01891-3
Source records
- pubmed · retrieved 2026-09-26T18:46:34.756Z
- europe-pmc · retrieved 2026-09-26T18:46:34.768Z